<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10726475</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.3c00479</article-id><article-categories><subj-group><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Atypical <italic>N</italic>-Alkyl to <italic>N</italic>-Noralkoxy Switch in a Dual cSRC/BCR-ABL1 Kinase
Inhibitor Improves Drug Efflux and hERG Affinity</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2251-5569</contrib-id><name><surname>Hill</surname><given-names>Jarvis</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Jones</surname><given-names>Robert M.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath3"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2400-0083</contrib-id><name><surname>Crich</surname><given-names>David</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Pharmaceutical and Biomedical Sciences, <institution>University of Georgia</institution>, Athens, Georgia 30602, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Chemistry, <institution>University of Georgia</institution>, Athens, Georgia 30602, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>Independent
Researcher</institution>, P.O. Box 568, Oakley, Utah 84055-0568, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>Complex
Carbohydrate Research Center, <institution>University
of Georgia</institution>, Athens, Georgia 30602, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>David.crich@uga.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>14</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>12</month><year>2023</year></pub-date><volume>14</volume><issue>12</issue><fpage>1869</fpage><lpage>1875</lpage><history><date date-type="received"><day>24</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>29</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00479_0004" id="ab-tgr1"/></p><p>We
describe an atypical
amine bioisostere, the trisubstituted hydroxylamine,
that upon incorporation into an approved dual cSRC/BCR-ABL1 kinase
inhibitor yields <bold>9</bold>, a compound that retains potent biological
activity and couples it with improved drug efflux and hERG affinity
at the expense of only a 2 atomic mass unit increase in molecular
weight. Contrary to the common expectation for hydroxylamines in medicinal
chemistry, <bold>9</bold> is well tolerated <italic>in vivo</italic> and lacks the mutagenicity and genotoxicity so often ascribed to
lesser substituted hydroxylamines. A matched molecular pair (MMP)
analysis suggests that the beneficial properties conferred by the <italic>N</italic>-alkyl to <italic>N</italic>-noralkoxy switch arises from
a reduction in basicity of the piperazine unit. Overall, these results
lend additional support to the use of trisubstituted hydroxylamines
as bioisosteres of <italic>N</italic>-alkyl groups that are not involved
in key polar interactions.</p></abstract><kwd-group><kwd>Bioisostere</kwd><kwd>Hydroxylamine</kwd><kwd>BCR-ABL1</kwd><kwd>Leukemia</kwd><kwd>hERG</kwd><kwd>Efflux</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution><institution-id institution-id-type="doi">10.13039/100000057</institution-id></institution-wrap></funding-source><award-id>GM144754</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada</institution><institution-id institution-id-type="doi">10.13039/501100000038</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Georgia Research Alliance</institution><institution-id institution-id-type="doi">10.13039/100008065</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>University of Georgia</institution><institution-id institution-id-type="doi">10.13039/100007699</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml3c00479</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml3c00479</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>We recently
described compound <bold>2</bold>, a hydroxylamine-bearing, orally
bioavailable, brain-penetrant,
selective epidermal growth factor receptor (EGFR) inhibitor with potential
for treating EGFR+ central nervous system (CNS) metastases in non-small-cell
lung cancer (NSCLC) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>a).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Key to the discovery of <bold>2</bold> was the recognition that derivatization of a saturated nitrogen
heterocycle in the form of a hydroxylamine could attenuate basicity
and modify the lipophilicity of the starting molecule, gefitinib (<bold>1</bold>), in such a way that <bold>2</bold> evades efflux by transporters,
such as P-glycoprotein (P-gp, or MDR1), and/or breast cancer resistance
protein (BCRP).<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref3">3</xref></sup> Unlike lesser substituted hydroxylamines<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> and structurally related hydroxamates,<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> which confer
mutagenicity by metabolic activation to electrophilic nitroso derivatives
or isocyanates and subsequent conjugation with DNA, <bold>2</bold> exhibited good stability <italic>in vitro</italic> and <italic>in
vivo</italic> and critically lacked both mutagenicity and genotoxicity.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup> We now describe the extension of this novel bioisosteric design
strategy to the FDA-approved small molecule drug, bosutinib (<bold>3</bold>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Overview of selected BCR-ABL1 inhibitors and the bioisosteric design
strategy deployed in this study. (A) Chemical structures of gefitinib
and the brain-penetrating EGFR inhibitor, <bold>2</bold>. (B) Chemical
structures of select BCR-ABL1 inhibitors and their liabilities against
efflux transporters or the hERG ion channel. (C) Proposed bioisosteric
replacement. (D) Chemical synthesis of <bold>9</bold>. <sup><italic>i</italic></sup>PrMgCl&#x000b7;LiCl, isopropylmagnesium chloride lithium
chloride; THF, tetrahydrofuran; TBAF, tetra-<italic>N</italic>-butylammonium
fluoride; SOCl<sub>2</sub>, thionyl chloride; NaH, sodium hydride;
DMF, dimethylformamide; HCl, hydrogen chloride.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00479_0001" id="gr1" position="float"/></fig><p>Bosutinib is approved for the treatment of chronic myeloid leukemia
(CML), a disease that comprises 15&#x02013;20% of all adult leukemia
cases worldwide and that is characterized by a reciprocal translocation
[t(9;22)(q34;q11)] of DNA between chromosomes 9 and 22 in hematologic
progenitor cells, which results in fusion of the <italic>ABL1</italic> (Abelson proto-oncogene 1, chromosome 9) and <italic>BCR</italic> (breakpoint cluster region, chromosome 22) genes on the Philadelphia
chromosome (Ph).<sup><xref ref-type="bibr" rid="ref10">10</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup> The first BCR-ABL1-targeted tyrosine kinase inhibitor (TKI), imatinib
(<bold>4</bold>), which received regulatory approval in 2001, ushered
in a new era of targeted drug discovery and turned a once fatal leukemia
into one in which the lifespan of patients now approaches that of
the general population.<sup><xref ref-type="bibr" rid="ref16">16</xref>&#x02212;<xref ref-type="bibr" rid="ref21">21</xref></sup> Unfortunately, acquired resistance to imatinib (<bold>4</bold>),
which appears in roughly 40% of all CML patients, is a significant
challenge in management of the disease.<sup><xref ref-type="bibr" rid="ref22">22</xref>&#x02212;<xref ref-type="bibr" rid="ref26">26</xref></sup> The search for drugs to treat CML in all phases with
acquired resistance to imatinib led to the discovery of second-generation
BCR-ABL1 inhibitors, such as bosutinib (<bold>3</bold>),<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> dasatinib (<bold>5</bold>),<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> and nilotinib (<bold>6</bold>),<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> and third-generation inhibitors ponatinib (<bold>7</bold>)<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> and asciminib (<bold>8</bold>)<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>b). Unfortunately, second- and third- generation BCR-ABL1 inhibitors
nilotinib and ponatinib have serious potential side-effects due to
inhibition of the human ether-&#x000e0;-go-go-related gene (hERG) potassium
ion channel, which significantly limits their use in the treatment
of CML.<sup><xref ref-type="bibr" rid="ref31">31</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> Indeed, nilotinib carries a black box warning for QT interval prolongation
and sudden death, while ponatinib carries a black box warning for
vascular occlusion, heart failure, and hepatotoxicity. While bosutinib,
dasatinib, and asciminib have lower affinity for the hERG ion channel,
these second- and third- generation BCR-ABL1 inhibitors are substrates
for efflux transporters P-gp and/or BCRP, which can confer indirect
inhibitor resistance through active drug efflux.<sup><xref ref-type="bibr" rid="ref36">36</xref>&#x02212;<xref ref-type="bibr" rid="ref39">39</xref></sup> Thus, developing potent inhibitors
of BCR-ABL1 with minimal affinity for the hERG ion channel and reduced
drug efflux is of significant interest for the clinical management
of Ph+ CML. Building on our previous results,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> we hypothesized that a bioisosteric replacement of the <italic>N</italic>-alkyl piperazine unit in bosutinib by an equivalent hydroxylamine <italic>N</italic>-noralkoxy unit would attenuate the basicity<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> and modify the lipophilicity<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> of bosutinib to reduce hERG affinity and efflux propensity
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>c). Herein,
we reduce this hypothesis to practice and report on the direct incorporation
of a trisubstituted hydroxylamine <italic>N</italic>-noralkoxy unit
into a bosutinib <italic>N</italic>-alkyl unit that leads to both
a reduction in hERG affinity and efflux propensity at the expense
of an insignificant molecular weight increase of 2 atomic mass units
(amu). These properties are all achieved while maintaining oral bioavailability
and potent antiproliferative activity in patient-derived Ph+ leukemia
cells and without the anticipated toxicity commonly surmised<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup> to accompany hydroxylamine units. Collectively, we provide additional
support for the use of trisubstituted hydroxylamines as bioisosteres
in medicinal chemistry.</p><p>The synthesis of <bold>9</bold> commenced
with our direct N&#x02013;O
bond-forming reaction<sup><xref ref-type="bibr" rid="ref40">40</xref>&#x02212;<xref ref-type="bibr" rid="ref42">42</xref></sup> that gave multigram-scale quantities of hydroxylamine
(<bold>12</bold>) in 62% yield upon reaction of the <italic>N</italic>-methylpiperazine (<bold>10</bold>)-derived magnesium amide with
the 2-methyltetrahydropyranyl (MTHP) monoperoxyacetal<sup><xref ref-type="bibr" rid="ref43">43</xref>&#x02212;<xref ref-type="bibr" rid="ref45">45</xref></sup> (<bold>11</bold>) derived from commercially available 2-[(<italic>tert</italic>-butyldimethylsilyl)oxy]ethanol (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>d). Deprotection of the <italic>tert</italic>-butyldimethylsilyl (TBS) group in <bold>12</bold> with tetra-<italic>N</italic>-butylammonium fluoride (TBAF) proceeded in 65% yield and
was followed by chlorination and displacement with phenol (<bold>14</bold>) under basic conditions to give quinoline (<bold>15</bold>) in 35%
yield over two steps. A nucleophilic aromatic substitution (S<sub>N</sub>Ar) reaction with aniline (<bold>16</bold>) under acidic conditions
then gave <bold>9</bold> in 29% yield.</p><p>With <bold>9</bold> in
hand, we initially evaluated biochemical
inhibition of the relevant mutant BCR-ABL1 kinases and found that <bold>9</bold> maintained strong inhibition of imatinib-resistant BCR-ABL1
mutants. As expected,<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> however, <bold>9</bold> showed reduced activity against BCR-ABL1<sup>T315I</sup> that bears the T315I &#x0201c;gatekeeper&#x0201d; mutation, which
disrupts the ATP binding region drug contact sites (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Moreover, <bold>9</bold> also
strongly inhibited cSRC, an additional target of bosutinib with an
IC<sub>50</sub> value of 2.0 nM.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Determination of
Kinase Inhibition
(IC<sub>50</sub>) of Bosutinib and <bold>9</bold> against Mutant BCR-ABL1
and cSRC</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">kinase</th><th style="border:none;" align="center" char=".">bosutinib<xref rid="t1fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" char="."><bold>9</bold></th></tr></thead><tbody><tr><td colspan="3" align="left">BCR-ABL1 IC<sub>50</sub>(nM)<xref rid="t1fn2" ref-type="table-fn">b</xref><sup>,</sup><xref rid="t1fn3" ref-type="table-fn">c</xref></td></tr><tr><td style="border:none;" align="left">wt</td><td style="border:none;" align="char" char=".">&#x0003c;1</td><td style="border:none;" align="char" char=".">&#x0003c;1</td></tr><tr><td style="border:none;" align="left">H396P</td><td style="border:none;" align="char" char=".">&#x0003c;1</td><td style="border:none;" align="char" char=".">&#x0003c;1</td></tr><tr><td style="border:none;" align="left">M351T</td><td style="border:none;" align="char" char=".">&#x0003c;1</td><td style="border:none;" align="char" char=".">&#x0003c;1</td></tr><tr><td style="border:none;" align="left">Q252H</td><td style="border:none;" align="char" char=".">&#x0003c;1</td><td style="border:none;" align="char" char=".">&#x0003c;1</td></tr><tr><td style="border:none;" align="left">T315I</td><td style="border:none;" align="char" char=".">44</td><td style="border:none;" align="char" char=".">47</td></tr><tr><td style="border:none;" align="left">Y253F</td><td style="border:none;" align="char" char=".">&#x0003c;1</td><td style="border:none;" align="char" char=".">&#x0003c;1</td></tr><tr><td colspan="3" align="left">cSRC IC<sub>50</sub>(nM)<xref rid="t1fn2" ref-type="table-fn">b</xref><sup>,</sup><xref rid="t1fn3" ref-type="table-fn">c</xref></td></tr><tr><td style="border:none;" align="left">wt</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">2</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Obtained from MedChemExpress (HY-10158).</p></fn><fn id="t1fn2"><label>b</label><p>Conducted by Eurofins Cerep, SA.</p></fn><fn id="t1fn3"><label>c</label><p>IC<sub>50</sub> represents mean
of <italic>n</italic> = 2 technical replicates conducted at [ATP]
= 10 &#x003bc;M.</p></fn></table-wrap-foot></table-wrap><p>Moving to <italic>in vitro</italic> ADMET properties of <bold>9</bold>, we first measured
lipophilicity, where <bold>9</bold> and bosutinib
had log<italic>D</italic><sub>7.4</sub> values of 3.5 and 3.1, respectively
(<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Despite
the increase in lipophilicity, <bold>9</bold> and bosutinib exhibited
similar solubility at pH 7.4 and comparable unbound plasma protein
fractions in human and rat. Both <bold>9</bold> and bosutinib showed
significant degradation in human and rat liver microsomes, while the
compounds exhibited comparably enhanced stability in hepatocytes.
We then tested for permeability in colon-carcinoma (Caco-2) cells
and Madin-Darby canine kidney (MDCK) MDCKII-MDR1 cells, with the former
expressing both P-gp and BCRP, and the latter overexpressing only
P-gp.<sup><xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> Gratifyingly, in the Caco-2 cell permeability
assay, we observed a 4-fold decrease in efflux ratio for <bold>9</bold> in comparison with bosutinib due to decreased efflux (basolateral
to apical direction). For the MDCKII-MDR1 cell line, differences between
bosutinib and <bold>9</bold> were much smaller in both directions,
thereby indicating overall that the direct <italic>N</italic>-noralkoxy
switch has minimal effect on P-gp substrate recognition in this series.
With respect to potential toxicity by hERG ion channel inhibition, <bold>9</bold> showed a significant increase (<italic>P</italic> = 0.0086;
unpaired Student&#x02019;s <italic>t</italic> test) in IC<sub>50</sub> value compared with bosutinib with IC<sub>50</sub> values of 3.41
and 1.01 &#x003bc;M, respectively, which translated into a reduced maximal
% hERG inhibition of 24 for <bold>9</bold> and 52 for bosutinib at
1 &#x003bc;M (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00479/suppl_file/ml3c00479_si_001.pdf">Supporting Information</ext-link> for details). In a CYP inhibition assay across isoforms 3A4, 2D6,
2C9, and 1A2, we observed no inhibition for <bold>9</bold> (IC<sub>50</sub> = &#x0003e;10 &#x003bc;M) except for moderate inhibition of CYP2D6
(IC<sub>50</sub> = 7.6 &#x003bc;M), which was negative in a follow-up
time-dependent inhibition (TDI) study in human liver microsomes (see
the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00479/suppl_file/ml3c00479_si_001.pdf">Supporting Information</ext-link> for details).
We then conducted an Ames fluctuation assay across four <italic>Salmonella</italic> strains (TA98, TA100, TA1537, and TA1535) and an <italic>in vitro</italic> micronucleus test in Chinese hamster ovary (CHO) cells, both with
and without metabolic activation by S9 (&#x000b1;S9), and found that <bold>9</bold> was neither mutagenic nor genotoxic (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00479/suppl_file/ml3c00479_si_001.pdf">Supporting Information</ext-link> for details).<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref></sup> Collectively, and consistent with our earlier work,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> we find that trisubstituted hydroxylamines are neither
inherently mutagenic nor genotoxic.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title><italic>In Vitro</italic> ADMET Properties
of Bosutinib and <bold>9</bold><xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">parameter</th><th style="border:none;" align="center">bosutinib<xref rid="t2fn2" ref-type="table-fn">b</xref></th><th style="border:none;" align="center"><bold>9</bold></th></tr></thead><tbody><tr><td style="border:none;" align="left">log<italic>D</italic><sub>7.4</sub><xref rid="t2fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">3.1</td><td style="border:none;" align="left">3.5</td></tr><tr><td style="border:none;" align="left">aq sol. (&#x003bc;M)<xref rid="t2fn4" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">14</td><td style="border:none;" align="left">12</td></tr><tr><td style="border:none;" align="left"><italic>f</italic><sub>u,&#x000a0;plasma</sub> % (H/R/M)<xref rid="t2fn5" ref-type="table-fn">e</xref></td><td style="border:none;" align="left">4.5/7.2/n.d.</td><td style="border:none;" align="left">5.0/6.5/2.8</td></tr><tr><td style="border:none;" align="left">LMCl<sub>int</sub> (H/R)<xref rid="t2fn6" ref-type="table-fn">f</xref></td><td style="border:none;" align="left">288/264</td><td style="border:none;" align="left">228/185</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (min) (H/R)<xref rid="t2fn6" ref-type="table-fn">f</xref></td><td style="border:none;" align="left">4.8/5.3</td><td style="border:none;" align="left">6.1/7.6</td></tr><tr><td style="border:none;" align="left">HEPCl<sub>int</sub> (H/R/M)<xref rid="t2fn7" ref-type="table-fn">g</xref></td><td style="border:none;" align="left">25.3/103.4/n.d.</td><td style="border:none;" align="left">34.3/178.2/60.1</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (min) (H/R/M)<xref rid="t2fn7" ref-type="table-fn">g</xref></td><td style="border:none;" align="left">54.9/13.4</td><td style="border:none;" align="left">40.4/7.8/23.1</td></tr><tr><td style="border:none;" align="left">Caco-2 <italic>P</italic><sub>app</sub> (a-b/b-a) (10<sup>&#x02013;6</sup>&#x000a0;cm/s)<xref rid="t2fn8" ref-type="table-fn">h</xref></td><td style="border:none;" align="left">0.9:10.9</td><td style="border:none;" align="left">1.1:4.0</td></tr><tr><td style="border:none;" align="left">Caco-2 ER<xref rid="t2fn8" ref-type="table-fn">h</xref></td><td style="border:none;" align="left">12.1</td><td style="border:none;" align="left">3.6</td></tr><tr><td style="border:none;" align="left">MDCKII-MDR1 <italic>P</italic><sub>app</sub> (a-b/b-a) (10<sup>&#x02013;6</sup>&#x000a0;cm/s)<xref rid="t2fn9" ref-type="table-fn">i</xref></td><td style="border:none;" align="left">0.4:11.3</td><td style="border:none;" align="left">0.5:10.3</td></tr><tr><td style="border:none;" align="left">MDCKII-MDR1 ER<xref rid="t2fn9" ref-type="table-fn">i</xref></td><td style="border:none;" align="left">28.3</td><td style="border:none;" align="left">20.6</td></tr><tr><td style="border:none;" align="left">hERG
(IC<sub>50</sub>) (&#x003bc;M)<xref rid="t2fn10" ref-type="table-fn">j</xref></td><td style="border:none;" align="left">1.01</td><td style="border:none;" align="left">3.41</td></tr><tr><td style="border:none;" align="left">%&#x000a0;hERG&#x000a0;inhibition (1&#x000a0;&#x003bc;M/10&#x000a0;&#x003bc;M)<xref rid="t2fn10" ref-type="table-fn">j</xref></td><td style="border:none;" align="left">52/93</td><td style="border:none;" align="left">24/83</td></tr><tr><td style="border:none;" align="left">CYP&#x000a0;(IC<sub>50</sub>)&#x000a0;(&#x003bc;M)<xref rid="t2fn11" ref-type="table-fn">k</xref>(3A4/2D6/2C9/1A2)</td><td style="border:none;" align="left">n.d.</td><td style="border:none;" align="left">24.7/7.6/13.3/&#x0003e;30</td></tr><tr><td style="border:none;" align="left">CYP 2D6 TDI<xref rid="t2fn11" ref-type="table-fn">k</xref></td><td style="border:none;" align="left">n.d.</td><td style="border:none;" align="left">negative</td></tr><tr><td style="border:none;" align="left">Ames<xref rid="t2fn12" ref-type="table-fn">l</xref></td><td style="border:none;" align="left">n.d.</td><td style="border:none;" align="left">negative</td></tr><tr><td style="border:none;" align="left">micronucleus<xref rid="t2fn13" ref-type="table-fn">m</xref></td><td style="border:none;" align="left">n.d.</td><td style="border:none;" align="left">negative</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Assayed by Pharmaron
Inc. and values
presented represent the mean of <italic>n</italic> = 2 technical replicates,
unless otherwise specified.</p></fn><fn id="t2fn2"><label>b</label><p>Obtained from MedChemExpress (catalog
no. HY-10158).</p></fn><fn id="t2fn3"><label>c</label><p>log<italic>D</italic><sub>7.4</sub> determined by the shake-flask method.</p></fn><fn id="t2fn4"><label>d</label><p>Solubility (&#x003bc;M) in aqueous
buffer at pH 7.4, <italic>n</italic> = 1.</p></fn><fn id="t2fn5"><label>e</label><p>Fraction of unbound drug in human,
rat, and mouse plasma was obtained with test concentration of 5 &#x003bc;M
by equilibrium dialysis.</p></fn><fn id="t2fn6"><label>f</label><p>Rate of metabolism (&#x003bc;L/min/mg)
in human and rat liver microsomes.</p></fn><fn id="t2fn7"><label>g</label><p>Rate of metabolism (&#x003bc;L/min/10<sup>6</sup> cells) in human,
rat, and mouse hepatocytes.</p></fn><fn id="t2fn8"><label>h</label><p>Parent compound (5 &#x003bc;M) was
incubated for 2 h at 37 &#x000b0;C. ER is the efflux ratio and is calculated
by <italic>P</italic><sub>app</sub> (b-a/a-b).</p></fn><fn id="t2fn9"><label>i</label><p>Parent compound (1 &#x003bc;M) was
incubated for 2 h at 37 &#x000b0;C. ER is the efflux ratio and is calculated
by <italic>P</italic><sub>app</sub> (b-a/a-b).</p></fn><fn id="t2fn10"><label>j</label><p>Obtained by manual patch-clamp
system. Five doses (30, 10, 3.33, 1.11, and 0.37 &#x003bc;M) were run
in triplicate, <italic>n</italic> = 3, for IC<sub>50</sub> determinations.</p></fn><fn id="t2fn11"><label>k</label><p>Low DDI is predicted with
only
minimal inhibition of CYP2D6 observed that was negative in a follow-up
TDI study.</p></fn><fn id="t2fn12"><label>l</label><p>Ames fluctuation
test performed
by Eurofins Panlabs with four common strains (TA98, TA100, TA1537,
and TA1535) with and without metabolic activation (&#x000b1;S9) at testing
concentrations of 5, 10, 50, and 100 &#x003bc;M. Negative result valid
up to 10 &#x003bc;M, after which bacterial cytotoxicity was observed.</p></fn><fn id="t2fn13"><label>m</label><p><italic>In vitro</italic> micronucleus
test performed by Eurofins Panlabs with and without metabolic activation
(&#x000b1;S9) at testing concentrations of 0.2, 0.5, 2, 5, 20, 50, 200,
and 500 &#x003bc;M. Negative result valid up to 20 &#x003bc;M + S9 and
5 &#x003bc;M &#x02013; S9, after which cytotoxicity was observed. Nonstandard
abbreviations: sol. solubility; DDI, drug-drug interactions; H, human;
R, rat; M, mouse; n.d., not determined.</p></fn></table-wrap-foot></table-wrap><p>We then probed the anticancer activity of <bold>9</bold> in four
patient-derived leukemia cell lines with bosutinib and cisplatin as
the positive controls in all experiments (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). We saw strong antiproliferative activity
of <bold>9</bold> in Ph+ CML cell lines, KU812 and MEG-01, which harbor
the most common p210 BCR-ABL1 isoform, with IC<sub>50</sub> values
in the single-digit (5.2 nM) to low double-digit (25 nM) nanomolar
range. In the Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15,
which bears a shorter p190 isoform of oncogenic BCR-ABL1, <bold>9</bold> showed reduced activity with an IC<sub>50</sub> value of 410 nM.
Finally, to confirm that the antiproliferative activity is due to
specific targeting of BCR-ABL1, <bold>9</bold> was assessed in the
leukemia cell line Molt-4, which is negative for BCR-ABL1, and the
compound exhibited a markedly decreased IC<sub>50</sub> value of &#x0003e;2
&#x003bc;M, as also seen with bosutinib.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p><italic>In vitro</italic> antiproliferative activity in patient-derived
leukemia cell lines. Compound <bold>9</bold> displays potent antiproliferative
activity in patient-derived Ph+ CML cell lines KU812 and MEG-01 (BCR-ABL1
isoform p210) and reduced activity in ALL cell line SUP-B15 (BCR-ABL1
isoform p190), while displaying minimal activity in Molt-4 (BCR-ABL1
negative). For all antiproliferative assays, points indicate the mean,
and
error bars indicate SD; <italic>n</italic> = 3 independent replicates;
IC<sub>50</sub> values (nM) are reported beside the dose&#x02013;response
curves and represent the mean &#x000b1; SEM. IC<sub>50</sub> (nM) values
are unadjusted for FBS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00479_0002" id="gr2" position="float"/></fig><p>We then assessed the
pharmacokinetic properties of <bold>9</bold> after administration
into healthy CD1-mice (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). No adverse events or signs of toxicity
were observed for the compound at the tested doses, which is consistent
with our previous study<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and in stark contrast
to the common belief<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup> that hydroxylamines are inherently
toxic. At 5 mg/kg intravenous (iv) and 50 mg/kg oral (po) dosing,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup><bold>9</bold> exhibited high oral bioavailability
(<italic>F</italic> = 71%) and exposure (AUC<sub>inf</sub> = 11&#x0202f;518
h&#x000b7;nM; unbound AUC<sub>u</sub> = 323 h&#x000b7;nM), an acceptable
half-life (<italic>t</italic><sub>1/2</sub> = 2.18 h), and a high
maximal plasma concentration (<italic>C</italic><sub>max</sub> = 1560
nM; unbound <italic>C</italic><sub>max</sub> = 44 nM). Overall, these
experiments suggested that <bold>9</bold> is an orally bioavailable,
potent inhibitor of BCR-ABL1 with reduced hERG affinity and reduced
efflux in Caco-2 cells, all of which were achieved through an insignificant
2 amu hike in molecular weight by incorporation of a putative &#x0201c;structural
alert.&#x0201d;<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref52">52</xref></sup></p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Pharmacokinetic
Profile of <bold>9</bold> in CD1 Mice (<italic>n</italic> = 3, per
Study Arm)<xref rid="t3fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th style="border:none;" align="center">dose</th><th style="border:none;" align="center">parameter</th><th style="border:none;" align="center" char="&#x000b1;">value</th></tr></thead><tbody><tr><td rowspan="3" style="border:none;" align="left">5&#x000a0;mg/kg iv</td><td style="border:none;" align="left">CL (mL/min/kg)<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="char" char="&#x000b1;">52.5&#x000a0;&#x000b1;&#x000a0;8.6</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub><italic>1/2</italic></sub> (hr)<xref rid="t3fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="char" char="&#x000b1;">2.18&#x000a0;&#x000b1;&#x000a0;0.24</td></tr><tr><td style="border:none;" align="left"><italic>V</italic><sub>ss</sub> (L/kg)<xref rid="t3fn4" ref-type="table-fn">d</xref></td><td style="border:none;" align="char" char="&#x000b1;">6.39&#x000a0;&#x000b1;&#x000a0;1.14</td></tr><tr><td rowspan="5" style="border:none;" align="left">50&#x000a0;mg/kg po</td><td style="border:none;" align="left"><italic>C</italic><sub>max</sub> (ng/mL)<xref rid="t3fn5" ref-type="table-fn">e</xref></td><td style="border:none;" align="char" char="&#x000b1;">1560&#x000a0;&#x000b1;&#x000a0;701</td></tr><tr><td style="border:none;" align="left"><italic>T</italic><sub>max</sub> (hr)<xref rid="t3fn6" ref-type="table-fn">f</xref></td><td style="border:none;" align="char" char="&#x000b1;">1.17&#x000a0;&#x000b1;&#x000a0;0.76</td></tr><tr><td style="border:none;" align="left">AUC<sub>inf</sub> (h&#x000b7;ng/mL)<xref rid="t3fn7" ref-type="table-fn">g</xref></td><td style="border:none;" align="char" char="&#x000b1;">11&#x0202f;519 &#x000b1; 1756</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (hr)<xref rid="t3fn8" ref-type="table-fn">h</xref></td><td style="border:none;" align="char" char="&#x000b1;">2.47&#x000a0;&#x000b1;&#x000a0;0.03</td></tr><tr><td style="border:none;" align="left"><italic>F</italic> (%)<xref rid="t3fn9" ref-type="table-fn">i</xref></td><td style="border:none;" align="char" char="&#x000b1;">71.1&#x000a0;&#x000b1;&#x000a0;10.8</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p><italic>In vivo</italic> pharmacokinetics
(PK) was performed by Pharmaron Inc. in healthy male CD1 mice (<italic>n</italic> = 3, per route) via an intravenous infusion route (DMSO/10%
captisol in saline = 1:99) and oral gavage route (0.5% CMC, 2.0% Tween
80, 0.06% acetic acid in H<sub>2</sub>O).</p></fn><fn id="t3fn2"><label>b</label><p>Clearance obtained from intravenous
infusion.</p></fn><fn id="t3fn3"><label>c</label><p>Mean elimination
half-life obtained
from intravenous infusion.</p></fn><fn id="t3fn4"><label>d</label><p>Volume of distribution at steady
state.</p></fn><fn id="t3fn5"><label>e</label><p>Peak plasma concentration.</p></fn><fn id="t3fn6"><label>f</label><p>Time to reach peak plasma concentration.</p></fn><fn id="t3fn7"><label>g</label><p>Area under concentration time
curve
from 0 to &#x0221e;.</p></fn><fn id="t3fn8"><label>h</label><p>Mean
elimination half-life obtained
from oral gavage.</p></fn><fn id="t3fn9"><label>i</label><p>Bioavailability
(%) calculated with
AUC<sub>inf</sub> and nominal dose. All values represent the mean
&#x000b1; SD.</p></fn></table-wrap-foot></table-wrap><p>We next sought
to probe the origins of improvement in drug efflux
and hERG affinity imparted by the <italic>N</italic>-alkyl to <italic>N</italic>-noralkoxy switch observed with <bold>9</bold> by a matched-molecular
pair (MMP)<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). To this end, we synthesized
the <italic>N</italic>-alkyl (<bold>17</bold>) and <italic>N</italic>-noralkoxy (<bold>18</bold>) derivatives of the 2-methoxyphenoxy-propyl-<italic>N</italic>-methylpiperazine scaffold present in bosutinib and determined
log<italic>D</italic><sub>7.4</sub>, aqueous solubility at pH 7.4
and the p<italic>K</italic>a values (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00479/suppl_file/ml3c00479_si_001.pdf">Supporting Information</ext-link> for details). We found that both derivatives exhibited
similar log<italic>D</italic><sub>7.4</sub> values (0.9 for <bold>17</bold> and 1.0 for <bold>18</bold>, respectively) and high solubility
(&#x0003e;250 &#x003bc;M at pH 7.4). With regard to basicity, the piperazine <bold>17</bold> exhibited two p<italic>K</italic>a values (p<italic>K</italic>a<sub>1</sub> = 4.2, p<italic>K</italic>a<sub>2</sub> = 8.1), as
is typical<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> of 1,2-diamines with protonation
of the one amine resulting in a dramatic reduction in basicity of
the second because of the inductive electron-withdrawing effect of
the ammonium ion. The alkoxy-substituted piperazine <bold>18</bold>, however, exhibited only a single p<italic>K</italic>a (p<italic>K</italic>a<sub>1</sub> = 7.4), which we attribute to the terminal <italic>N</italic>-methylamine whose basicity is reduced from the more typical
value seen in <bold>17</bold> by the additional electron-withdrawing
effect of the &#x003b4;-oxygen atom. The magnitude of this effect (&#x00394;p<italic>K</italic>a = &#x02212;0.7) is comparable with the reduction in p<italic>K</italic>a of a simple tertiary amine (<bold>19</bold>) upon introduction
of ether (<bold>20</bold>, &#x00394;p<italic>K</italic>a = &#x02212;0.8)
or hydroxy (<bold>21</bold>, &#x00394;p<italic>K</italic>a = &#x02212;0.9)
functionalities at the &#x003b4;-position.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> The basicity of the hydroxylamine unit in <bold>18</bold> is reduced
below the p<italic>K</italic>a of simple hydroxylamine (p<italic>K</italic>a = 5.9)<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> by the electron-withdrawing
effect of the ammonium ion arising from protonation of the terminal <italic>N</italic>-methylamine, thereby placing it outside the range of the
measurement (pH &#x02248; 2&#x02013;12). Thus, we propose that the observed
improvement in drug efflux in Caco-2 cells and hERG affinity imparted
by the <italic>N</italic>-alkyl to <italic>N</italic>-noralkoxy switch
in piperazines is due to the reduction in p<italic>K</italic>a (both
p<italic>K</italic>a<sub>1</sub> and p<italic>K</italic>a<sub>2</sub>) wrought by the introduction of the electronegative oxygen atom.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Matched
molecular pair (MMP) analysis on the 2-methoxyphenoxy-propyl-<italic>N</italic>-methylpiperazine scaffold and p<italic>K</italic>a values
of related &#x003b4;-alkoxy substituted amines. (A) MMP analysis of
a bosutinib fragment. All measurements were assayed by Pharmaron Inc.,
and values presented represent the mean of <italic>n</italic> = 2
technical replicates, unless otherwise specified. log<italic>D</italic><sub>7.4</sub> was determined by the shake-flask method. Solubility
(&#x003bc;M) in aqueous buffer was measured at pH 7.4, <italic>n</italic> = 1. p<italic>K</italic>a values were determined by the pH-metric
method. (B) Reported<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> p<italic>K</italic>a values of related dimethylamines highlighting similarities in p<italic>K</italic>a values of &#x003b4;-alkoxy substitution patterns.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00479_0003" id="gr3" position="float"/></fig><p>Innovative bioisosteres that improve drug properties
without significantly
increasing molecular weight are highly sought after in drug discovery.
In this letter, a direct bioisosteric replacement of the <italic>N</italic>-alkyl unit in a dual cSRC/BCR-ABL1 kinase inhibitor for an atypical
amine bioisostere, the trisubstituted hydroxylamine unit, is reported.
The insignificant 2 amu increase in molecular weight is achieved without
the loss of biological activity and with improvement in key drug properties,
such as hERG inhibition and drug efflux. Consistent with our previous
work,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup><bold>9</bold> critically lacks
both mutagenicity and genotoxicity while maintaining oral bioavailability
and achieving high free drug exposures <italic>in vivo</italic> with
no evidence of acute toxicity. A MMP analysis suggests that the benefits
conferred by the <italic>N</italic>-alkyl to <italic>N</italic>-noralkoxy
switch arise from a reduction in basicity of the piperazine heterocycle.
Collectively, these results lend additional support for the use of
trisubstituted hydroxylamines as novel bioisosteres of <italic>N</italic>-alkyl units in biologically active molecules and should better position
the community to apply this underrepresented functional group in the
discovery of leads residing in previously uncharted chemical space.</p></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00479?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00479</ext-link>.<list id="silist" list-type="simple"><list-item><p>Additional <italic>in vitro</italic> ADMET data, biological
materials and methods, synthetic procedures, characterization data,
Supplementary Tables S1&#x02013;S28, Supplementary Figures S1&#x02013;S7,
NMR spectra, and references (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00479/suppl_file/ml3c00479_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00479_si_001.pdf"><caption><p>ml3c00479_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p>J.H. and DC.
conceived the study with input from R.M.J. D.C. directed the study.
J.H. carried out the synthetic work. J.H. oversaw the experiments
performed by the contract research organizations. All authors contributed
to the discussion and analysis of the experiments. J.H. and D.C. wrote
the manuscript. All authors contributed to the discussion and analysis
of the experiments and commented on the manuscript.</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare the following competing financial interest(s): J.H. and D.C.
are cofounders of and hold equity in Hydroxalogs Biosciences, a startup
exploring the use of hydroxylamines in medicinal chemistry. J.H. and
D.C. are inventors on US Provisional Application 63/497,469 submitted
by the University of Georgia Research Foundation (UGARF), that covers
compound <bold>9</bold> described in this letter.</p></notes><ack><title>Acknowledgments</title><p>The authors thank the scientists at
Pharmaron, Eurofins,
and Crown Biosciences for their expert help. D.C. gratefully acknowledges
support from the National Institutes of Health (GM144754), the University
of Georgia, and the Georgia Research Alliance (GRA). J.H. was supported
by a Natural Sciences and Engineering Research Council of Canada (NSERC)
PGS-D scholarship.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ABL1</term><def><p>Abelson murine leukemia viral oncogene
homologue 1</p></def></def-item><def-item><term>ALL</term><def><p>acute lymphoblastic leukemia</p></def></def-item><def-item><term>Aq. Sol.</term><def><p>aqueous solubility</p></def></def-item><def-item><term>BCRP</term><def><p>breast cancer resistance protein</p></def></def-item><def-item><term>Caco-2</term><def><p>colon carcinoma
cell line</p></def></def-item><def-item><term><italic>C</italic><sub>max</sub></term><def><p>maximal concentration</p></def></def-item><def-item><term>cSRC</term><def><p>proto-oncogene tyrosine-protein
kinase Src</p></def></def-item><def-item><term>CHO</term><def><p>Chinese
hamster ovary</p></def></def-item><def-item><term>DDI</term><def><p>drug-drug interactions</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term><italic>f</italic><sub>u</sub></term><def><p>fraction unbound</p></def></def-item><def-item><term>H</term><def><p>human</p></def></def-item><def-item><term>HEPCl<sub>int</sub></term><def><p>intrinsic clearance
in hepatocytes</p></def></def-item><def-item><term><sup><italic>i</italic></sup>PrMgCl&#x000b7;LiCl</term><def><p>isopropylmagnesium chloride
lithium chloride</p></def></def-item><def-item><term>LMCl<sub>int</sub></term><def><p>intrinsic clearance in liver microsomes</p></def></def-item><def-item><term>log<italic>D</italic><sub>7.4</sub></term><def><p>logarithm of distribution at pH 7.4</p></def></def-item><def-item><term>M</term><def><p>mouse</p></def></def-item><def-item><term>MDCK</term><def><p>madine-darby canine kidney cell line</p></def></def-item><def-item><term>MMP</term><def><p>matched molecular pair</p></def></def-item><def-item><term>MTHP</term><def><p>2-methyltetrahydropyranyl</p></def></def-item><def-item><term>nd</term><def><p>not determined</p></def></def-item><def-item><term>NSCLC</term><def><p>nonsmall-cell
lung cancer</p></def></def-item><def-item><term><italic>P</italic><sub>app</sub></term><def><p>apparent permeability</p></def></def-item><def-item><term>Ph</term><def><p>Philadelphia</p></def></def-item><def-item><term>R</term><def><p>rat</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SEM</term><def><p>standard error of the mean</p></def></def-item><def-item><term>Sol.</term><def><p>solubility</p></def></def-item><def-item><term>TDI</term><def><p>time-dependent inhibition</p></def></def-item><def-item><term>TKI</term><def><p>tyrosine kinase inhibitor</p></def></def-item><def-item><term><italic>T</italic><sub>max</sub></term><def><p>time to reach maximal concentration</p></def></def-item><def-item><term><italic>V</italic><sub>ss</sub></term><def><p>volume
of distribution at steady state</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Hill</surname><given-names>J.</given-names></name>; <name><surname>Jones</surname><given-names>R. M.</given-names></name>; <name><surname>Crich</surname><given-names>D.</given-names></name>
<article-title>Discovery of a hydroxylamine-based
brain penetrant EGFR inhibitor for metastatic non-small-cell lung
cancer</article-title>. <source>J. Med. Chem.</source>
<year>2023</year>, <volume>66</volume> (<issue>22</issue>), <fpage>15477</fpage>&#x02013;<lpage>15492</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c01669</pub-id>.<pub-id pub-id-type="pmid">37934858</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Mollin</surname><given-names>J.</given-names></name>; <name><surname>Kasp&#x000e1;rek</surname><given-names>F.</given-names></name>; <name><surname>Lasovsk&#x000fd;</surname><given-names>J.</given-names></name>
<article-title>On the basicity of hydroxylamine
and its derivatives</article-title>. <source>Chem. Zvesti</source>
<year>1975</year>, <volume>29</volume> (<issue>1</issue>), <fpage>39</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Hill</surname><given-names>J.</given-names></name>; <name><surname>Crich</surname><given-names>D.</given-names></name>
<article-title>The <italic>N,N,O</italic>-trisubstituted hydroxylamine isostere
and its influence on lipophilicity and related parameters</article-title>. <source>ACS Med. Chem. Lett.</source>
<year>2022</year>, <volume>13</volume> (<issue>5</issue>), <fpage>799</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1021/acsmedchemlett.1c00713</pub-id>.<pub-id pub-id-type="pmid">35586423</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Davis</surname><given-names>C. D.</given-names></name>; <name><surname>Schut</surname><given-names>H. A. J.</given-names></name>; <name><surname>Snyderwine</surname><given-names>E. G.</given-names></name>
<article-title>Enzymatic
phase II activation of
the <italic>N</italic>-hydroxylamines of IQ and MeIQx and PhIP by
various organs of monkeys and rats</article-title>. <source>Cacinogenesis</source>
<year>1993</year>, <volume>14</volume> (<issue>10</issue>), <fpage>2091</fpage>&#x02013;<lpage>2096</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/14.10.2091</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Davis</surname><given-names>C. D.</given-names></name>; <name><surname>Ghoshal</surname><given-names>A.</given-names></name>; <name><surname>Schut</surname><given-names>H. A. J.</given-names></name>; <name><surname>Snyderwine</surname><given-names>E. G.</given-names></name>
<article-title>Metabolic
activation of heterocyclic amine food mutagens in the mammary gland
of lactating fischer 344 rats</article-title>. <source>Cancer Lett.</source>
<year>1994</year>, <volume>84</volume> (<issue>1</issue>), <fpage>67</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3835(94)90359-X</pub-id>.<pub-id pub-id-type="pmid">7915639</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Shen</surname><given-names>S.</given-names></name>; <name><surname>Kozikowski</surname><given-names>A. P.</given-names></name>
<article-title>Why hydroxamates
may not be the best histone deacetylase
inhibitors - what some may have forgotten or would rather forget?</article-title>. <source>ChemMedChem.</source>
<year>2016</year>, <volume>11</volume> (<issue>1</issue>), <fpage>15</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201500486</pub-id>.<pub-id pub-id-type="pmid">26603496</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Citarella</surname><given-names>A.</given-names></name>; <name><surname>Moi</surname><given-names>D.</given-names></name>; <name><surname>Pinzi</surname><given-names>L.</given-names></name>; <name><surname>Bonanni</surname><given-names>D.</given-names></name>; <name><surname>Rastelli</surname><given-names>G.</given-names></name>
<article-title>Hydroxamic acid derivatives:
From synthetic strategies to medicinal chemistry applications</article-title>. <source>ACS Omega</source>
<year>2021</year>, <volume>6</volume> (<issue>34</issue>), <fpage>21843</fpage>&#x02013;<lpage>21849</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.1c03628</pub-id>.<pub-id pub-id-type="pmid">34497879</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Reynisson</surname><given-names>J.</given-names></name>
<article-title>Bond stability
of the &#x0201c;undesirable&#x0201d; heteroatom-heteroatom
molecular moieties for high-throughput screening libraries</article-title>. <source>Eur. J. Med. Chem.</source>
<year>2011</year>, <volume>46</volume> (<issue>12</issue>), <fpage>5833</fpage>&#x02013;<lpage>5837</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2011.09.044</pub-id>.<pub-id pub-id-type="pmid">22000918</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Bruns</surname><given-names>B. F.</given-names></name>; <name><surname>Watson</surname><given-names>I. A.</given-names></name>
<article-title>Rules for identifying
potentially reactive or promiscuous
compounds</article-title>. <source>J. Med. Chem.</source>
<year>2012</year>, <volume>55</volume> (<issue>22</issue>), <fpage>9763</fpage>&#x02013;<lpage>9772</lpage>. <pub-id pub-id-type="doi">10.1021/jm301008n</pub-id>.<pub-id pub-id-type="pmid">23061697</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Epstein</surname><given-names>F. H.</given-names></name>; <name><surname>Kurzrock</surname><given-names>R.</given-names></name>; <name><surname>Gutterman</surname><given-names>J. U.</given-names></name>; <name><surname>Talpaz</surname><given-names>M.</given-names></name>
<article-title>The molecular genetics
of Philadelphia chromosome-positive leukemias</article-title>. <source>N. Engl. J. Med.</source>
<year>1988</year>, <volume>319</volume> (<issue>15</issue>), <fpage>990</fpage>&#x02013;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198810133191506</pub-id>.<pub-id pub-id-type="pmid">3047582</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Lugo</surname><given-names>T. G.</given-names></name>; <name><surname>Pendergast</surname><given-names>A. M.</given-names></name>; <name><surname>Muller</surname><given-names>A. J.</given-names></name>; <name><surname>Witte</surname><given-names>O. N.</given-names></name>
<article-title>Tyrosine
kinase
activity and transformation potency of BCR-ABL oncogene products</article-title>. <source>Science</source>
<year>1990</year>, <volume>247</volume> (<issue>4946</issue>), <fpage>1079</fpage>&#x02013;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1126/science.2408149</pub-id>.<pub-id pub-id-type="pmid">2408149</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Flis</surname><given-names>S.</given-names></name>; <name><surname>Chojnacki</surname><given-names>T.</given-names></name>
<article-title>Chronic myelogenous
leukemia, a still unsolved problem:
pitfalls and new therapeutic possibilities</article-title>. <source>Drug Des. Devel. Ther.</source>
<year>2019</year>, <volume>13</volume>, <fpage>825</fpage>&#x02013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S191303</pub-id>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Advani</surname><given-names>A. S.</given-names></name>; <name><surname>Pendergast</surname><given-names>A. M.</given-names></name>
<article-title>Bcr-Abl Variants: Biological and clinical aspects</article-title>. <source>Leuk. Res.</source>
<year>2002</year>, <volume>26</volume> (<issue>8</issue>), <fpage>713</fpage>&#x02013;<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1016/S0145-2126(01)00197-7</pub-id>.<pub-id pub-id-type="pmid">12191565</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Hantschel</surname><given-names>O.</given-names></name>
<article-title>Structure,
regulation, signaling, and targeting of Abl kinases in cancer</article-title>. <source>Genes Cancer</source>
<year>2012</year>, <volume>3</volume> (<issue>5&#x02013;6</issue>), <fpage>436</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1177/1947601912458584</pub-id>.<pub-id pub-id-type="pmid">23226581</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Puttini</surname><given-names>M.</given-names></name>; <name><surname>Coluccia</surname><given-names>A. M. L.</given-names></name>; <name><surname>Boschelli</surname><given-names>F.</given-names></name>; <name><surname>Cleris</surname><given-names>L.</given-names></name>; <name><surname>Marchesi</surname><given-names>E.</given-names></name>; <name><surname>Donella-Deana</surname><given-names>A.</given-names></name>; <name><surname>Ahmed</surname><given-names>S.</given-names></name>; <name><surname>Redaelli</surname><given-names>S.</given-names></name>; <name><surname>Piazza</surname><given-names>R.</given-names></name>; <name><surname>Magistroni</surname><given-names>V.</given-names></name>; <name><surname>Andreoni</surname><given-names>F.</given-names></name>; <name><surname>Scapozza</surname><given-names>L.</given-names></name>; <name><surname>Formelli</surname><given-names>F.</given-names></name>; <name><surname>Gambacorti-Passerini</surname><given-names>C.</given-names></name>
<article-title>In vitro and
in vivo activity of SKI-606, a novel Src-Abl
inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells</article-title>. <source>Cancer Res.</source>
<year>2006</year>, <volume>66</volume> (<issue>23</issue>), <fpage>11314</fpage>&#x02013;<lpage>11322</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1199</pub-id>.<pub-id pub-id-type="pmid">17114238</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Druker</surname><given-names>B. J.</given-names></name>; <name><surname>Tamura</surname><given-names>S.</given-names></name>; <name><surname>Buchdunger</surname><given-names>E.</given-names></name>; <name><surname>Ohno</surname><given-names>S.</given-names></name>; <name><surname>Segal</surname><given-names>G. M.</given-names></name>; <name><surname>Fanning</surname><given-names>S.</given-names></name>; <name><surname>Zimmermann</surname><given-names>J.</given-names></name>; <name><surname>Lydon</surname><given-names>N. B.</given-names></name>
<article-title>Effects of a selective
inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive
cells</article-title>. <source>Nat. Med.</source>
<year>1996</year>, <volume>2</volume> (<issue>5</issue>), <fpage>561</fpage>&#x02013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1038/nm0596-561</pub-id>.<pub-id pub-id-type="pmid">8616716</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Hochhaus</surname><given-names>A.</given-names></name>; <name><surname>O&#x02019;Brien</surname><given-names>S. G.</given-names></name>; <name><surname>Guilhot</surname><given-names>F.</given-names></name>; <name><surname>Druker</surname><given-names>B. J.</given-names></name>; <name><surname>Branford</surname><given-names>S.</given-names></name>; <name><surname>Foroni</surname><given-names>L.</given-names></name>; <name><surname>Goldman</surname><given-names>J. M.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>M. C.</given-names></name>; <name><surname>Radich</surname><given-names>J. P.</given-names></name>; <name><surname>Rudoltz</surname><given-names>M.</given-names></name>; <name><surname>Mone</surname><given-names>M.</given-names></name>; <name><surname>Gathmann</surname><given-names>I.</given-names></name>; <name><surname>Hughes</surname><given-names>T. P.</given-names></name>; <name><surname>Larson</surname><given-names>R. A.</given-names></name>
<article-title>IRIS Investigators.
Six-year follow-up
of patients receiving imatinib for the first-line treatment of chronic
myeloid leukemia</article-title>. <source>Leukemia</source>
<year>2009</year>, <volume>23</volume> (<issue>6</issue>), <fpage>1054</fpage>&#x02013;<lpage>1061</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2009.38</pub-id>.<pub-id pub-id-type="pmid">19282833</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Druker</surname><given-names>B. J.</given-names></name>; <name><surname>Guilhot</surname><given-names>F.</given-names></name>; <name><surname>O&#x02019;Brien</surname><given-names>S. G.</given-names></name>; <name><surname>Gathmann</surname><given-names>I.</given-names></name>; <name><surname>Kantarjian</surname><given-names>H.</given-names></name>; <name><surname>Gattermann</surname><given-names>N.</given-names></name>; <name><surname>Deininger</surname><given-names>M. W. N.</given-names></name>; <name><surname>Silver</surname><given-names>R. T.</given-names></name>; <name><surname>Goldman</surname><given-names>J. M.</given-names></name>; <name><surname>Stone</surname><given-names>R. M.</given-names></name>; <name><surname>Cervantes</surname><given-names>F.</given-names></name>; <name><surname>Hochhaus</surname><given-names>A.</given-names></name>; <name><surname>Powell</surname><given-names>B. L.</given-names></name>; <name><surname>Gabrilove</surname><given-names>J. L.</given-names></name>; <name><surname>Rousselot</surname><given-names>P.</given-names></name>; <name><surname>Reiffers</surname><given-names>J.</given-names></name>; <name><surname>Cornelissen</surname><given-names>J. J.</given-names></name>; <name><surname>Hughes</surname><given-names>T.</given-names></name>; <name><surname>Agis</surname><given-names>H.</given-names></name>; <name><surname>Fischer</surname><given-names>T.</given-names></name>; <name><surname>Verhoef</surname><given-names>G.</given-names></name>; <name><surname>Shepherd</surname><given-names>J.</given-names></name>; <name><surname>Saglio</surname><given-names>G.</given-names></name>; <name><surname>Gratwohl</surname><given-names>A.</given-names></name>; <name><surname>Nielsen</surname><given-names>J. L.</given-names></name>; <name><surname>Radich</surname><given-names>J. P.</given-names></name>; <name><surname>Simonsson</surname><given-names>B.</given-names></name>; <name><surname>Taylor</surname><given-names>K.</given-names></name>; <name><surname>Baccarani</surname><given-names>M.</given-names></name>; <name><surname>So</surname><given-names>C.</given-names></name>; <name><surname>Letvak</surname><given-names>L.</given-names></name>; <name><surname>Larson</surname><given-names>R. A.</given-names></name>
<article-title>IRIS Investigators. Five-year follow-up
of patients receiving imatinib for chronic myeloid leukemia</article-title>. <source>N. Engl. J. Med.</source>
<year>2006</year>, <volume>355</volume> (<issue>23</issue>), <fpage>2408</fpage>&#x02013;<lpage>2417</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa062867</pub-id>.<pub-id pub-id-type="pmid">17151364</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Cohen</surname><given-names>P.</given-names></name>; <name><surname>Cross</surname><given-names>D.</given-names></name>; <name><surname>J&#x000e4;nne</surname><given-names>P. A.</given-names></name>
<article-title>Kinase
drug discovery 20 years after
imatinib: Progress and future directions</article-title>. <source>Nat.
Rev. Drug Discovery</source>
<year>2021</year>, <volume>20</volume> (<issue>7</issue>), <fpage>551</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-021-00195-4</pub-id>.<pub-id pub-id-type="pmid">34002056</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Attwood</surname><given-names>M. M.</given-names></name>; <name><surname>Fabbro</surname><given-names>D.</given-names></name>; <name><surname>Sokolov</surname><given-names>A. V.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>; <name><surname>Schl&#x000f6;th</surname><given-names>H. B.</given-names></name>
<article-title>Trends
in kinase drug discovery: Targets, indications and inhibitor design</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2021</year>, <volume>20</volume> (<issue>11</issue>), <fpage>839</fpage>&#x02013;<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-021-00252-y</pub-id>.<pub-id pub-id-type="pmid">34354255</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Ayala-Aguilera</surname><given-names>C. C.</given-names></name>; <name><surname>Valero</surname><given-names>T.</given-names></name>; <name><surname>Lorente-Mac&#x000ed;as</surname><given-names>C1.</given-names></name>; <name><surname>Baillache</surname><given-names>D. J.</given-names></name>; <name><surname>Croke</surname><given-names>S.</given-names></name>; <name><surname>Unciti-Broceta</surname><given-names>A.</given-names></name>
<article-title>Small molecule
kinase inhibitor drugs
(1995&#x02013;2021): Medical indication, pharmacology, and synthesis</article-title>. <source>J. Med. Chem.</source>
<year>2022</year>, <volume>65</volume> (<issue>2</issue>), <fpage>1047</fpage>&#x02013;<lpage>1131</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00963</pub-id>.<pub-id pub-id-type="pmid">34624192</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Gorre</surname><given-names>M. E.</given-names></name>; <name><surname>Mohammed</surname><given-names>M.</given-names></name>; <name><surname>Ellwood</surname><given-names>K.</given-names></name>; <name><surname>Hsu</surname><given-names>N.</given-names></name>; <name><surname>Paquette</surname><given-names>R.</given-names></name>; <name><surname>Rao</surname><given-names>P. N.</given-names></name>; <name><surname>Sawyers</surname><given-names>C. L.</given-names></name>
<article-title>Clinical resistance
to STI-571 cancer
therapy caused by BCR-ABL gene mutation or amplification</article-title>. <source>Science</source>
<year>2001</year>, <volume>293</volume> (<issue>5531</issue>), <fpage>876</fpage>&#x02013;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1126/science.1062538</pub-id>.<pub-id pub-id-type="pmid">11423618</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Von
Bubnoff</surname><given-names>N.</given-names></name>; <name><surname>Schneller</surname><given-names>F.</given-names></name>; <name><surname>Peschel</surname><given-names>C.</given-names></name>; <name><surname>Duyster</surname><given-names>J.</given-names></name>
<article-title>BCR-ABL Gene
mutation in relation to clinical resistance of Philadelphia-chromosome-positive
leukaemia to STI571: A prospective study</article-title>. <source>Lancet</source>
<year>2002</year>, <volume>359</volume> (<issue>9305</issue>), <fpage>487</fpage>&#x02013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(02)07679-1</pub-id>.<pub-id pub-id-type="pmid">11853795</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Hochhaus</surname><given-names>A.</given-names></name>; <name><surname>Kreil</surname><given-names>S.</given-names></name>; <name><surname>Corbin</surname><given-names>A. S.</given-names></name>; <name><surname>La Ros&#x000e9;e</surname><given-names>P.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>M. C.</given-names></name>; <name><surname>Lahaye</surname><given-names>T.</given-names></name>; <name><surname>Hanfstein</surname><given-names>C.</given-names></name>; <name><surname>Schoch</surname><given-names>C.</given-names></name>; <name><surname>Cross</surname><given-names>N. C. P.</given-names></name>; <name><surname>Berger</surname><given-names>U.</given-names></name>; <name><surname>Gschaidmeier</surname><given-names>H.</given-names></name>; <name><surname>Druker</surname><given-names>B. J.</given-names></name>; <name><surname>Hehlmann</surname><given-names>R.</given-names></name>
<article-title>Molecular and chromosomal mechanisms
of resistance to imatinib (STI571) therapy</article-title>. <source>Leukemia</source>
<year>2002</year>, <volume>16</volume> (<issue>11</issue>), <fpage>2190</fpage>&#x02013;<lpage>2196</lpage>. <pub-id pub-id-type="doi">10.1038/sj.leu.2402741</pub-id>.<pub-id pub-id-type="pmid">12399961</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Apperley</surname><given-names>J. F.</given-names></name>
<article-title>Part II:
Management of resistance to imatinib in chronic myeloid leukaemia</article-title>. <source>Lancet Oncol.</source>
<year>2007</year>, <volume>8</volume> (<issue>12</issue>), <fpage>1116</fpage>&#x02013;<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(07)70379-0</pub-id>.<pub-id pub-id-type="pmid">18054881</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Braun</surname><given-names>T. P.</given-names></name>; <name><surname>Eide</surname><given-names>C. A.</given-names></name>; <name><surname>Druker</surname><given-names>B. J.</given-names></name>
<article-title>Response
and resistance to BCR-ABL1-targeted
therapies</article-title>. <source>Cancer Cell</source>
<year>2020</year>, <volume>37</volume> (<issue>4</issue>), <fpage>530</fpage>&#x02013;<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.03.006</pub-id>.<pub-id pub-id-type="pmid">32289275</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Lombardo</surname><given-names>L. J.</given-names></name>; <name><surname>Lee</surname><given-names>F. Y.</given-names></name>; <name><surname>Chen</surname><given-names>P.</given-names></name>; <name><surname>Norris</surname><given-names>D.</given-names></name>; <name><surname>Barrish</surname><given-names>J. C.</given-names></name>; <name><surname>Behnia</surname><given-names>K.</given-names></name>; <name><surname>Castaneda</surname><given-names>S.</given-names></name>; <name><surname>Cornelius</surname><given-names>L. A. M.</given-names></name>; <name><surname>Das</surname><given-names>J.</given-names></name>; <name><surname>Doweyko</surname><given-names>A. M.</given-names></name>; <name><surname>Fairchild</surname><given-names>C.</given-names></name>; <name><surname>Hunt</surname><given-names>J. T.</given-names></name>; <name><surname>Inigo</surname><given-names>I.</given-names></name>; <name><surname>Johnston</surname><given-names>K.</given-names></name>; <name><surname>Kamath</surname><given-names>A.</given-names></name>; <name><surname>Kan</surname><given-names>D.</given-names></name>; <name><surname>Klei</surname><given-names>H.</given-names></name>; <name><surname>Marathe</surname><given-names>P.</given-names></name>; <name><surname>Pang</surname><given-names>S.</given-names></name>; <name><surname>Peterson</surname><given-names>R.</given-names></name>; <name><surname>Pitt</surname><given-names>S.</given-names></name>; <name><surname>Schieven</surname><given-names>G. L.</given-names></name>; <name><surname>Schmidt</surname><given-names>R. J.</given-names></name>; <name><surname>Tokarski</surname><given-names>J.</given-names></name>; <name><surname>Wen</surname><given-names>M.-L.</given-names></name>; <name><surname>Wityak</surname><given-names>J.</given-names></name>; <name><surname>Borzilleri</surname><given-names>R. M.</given-names></name>
<article-title>Discovery
of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-Yl)-2-methylpyridimidin-4-ylamino)thiazole-5-carboxamide
(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor
activity in preclinical assays</article-title>. <source>J. Med. Chem.</source>
<year>2004</year>, <volume>47</volume> (<issue>27</issue>), <fpage>6658</fpage>&#x02013;<lpage>6661</lpage>. <pub-id pub-id-type="doi">10.1021/jm049486a</pub-id>.<pub-id pub-id-type="pmid">15615512</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Weisberg</surname><given-names>E.</given-names></name>; <name><surname>Manley</surname><given-names>P. W.</given-names></name>; <name><surname>Breitenstein</surname><given-names>W.</given-names></name>; <name><surname>Bruggen</surname><given-names>J.</given-names></name>; <name><surname>Cowan-Jacob</surname><given-names>S. W.</given-names></name>; <name><surname>Ray</surname><given-names>A.</given-names></name>; <name><surname>Huntly</surname><given-names>B.</given-names></name>; <name><surname>Fabbro</surname><given-names>D.</given-names></name>; <name><surname>Fendrich</surname><given-names>G.</given-names></name>; <name><surname>Hall-Meyers</surname><given-names>E.</given-names></name>; <name><surname>Kung</surname><given-names>A. L.</given-names></name>; <name><surname>Mestan</surname><given-names>J.</given-names></name>; <name><surname>Daley</surname><given-names>G. Q.</given-names></name>; <name><surname>Callahan</surname><given-names>L.</given-names></name>; <name><surname>Catley</surname><given-names>L.</given-names></name>; <name><surname>Cavazza</surname><given-names>C.</given-names></name>; <name><surname>Mohammed</surname><given-names>A.</given-names></name>; <name><surname>Neuberg</surname><given-names>D.</given-names></name>; <name><surname>Wright</surname><given-names>R. D.</given-names></name>; <name><surname>Gilliland</surname><given-names>D. G.</given-names></name>; <name><surname>Griffin</surname><given-names>J. D.</given-names></name>
<article-title>Characterization
of AMN107, a selective inhibitor of native and mutant Bcr-Abl</article-title>. <source>Cancer Cell</source>
<year>2005</year>, <volume>7</volume> (<issue>2</issue>), <fpage>129</fpage>&#x02013;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2005.01.007</pub-id>.<pub-id pub-id-type="pmid">15710326</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Huang</surname><given-names>W.-S.</given-names></name>; <name><surname>Metcalf</surname><given-names>C. A.</given-names></name>; <name><surname>Sundaramoorthi</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zou</surname><given-names>D.</given-names></name>; <name><surname>Thomas</surname><given-names>R. M.</given-names></name>; <name><surname>Zhu</surname><given-names>X.</given-names></name>; <name><surname>Cai</surname><given-names>L.</given-names></name>; <name><surname>Wen</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Romero</surname><given-names>J.</given-names></name>; <name><surname>Qi</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>I.</given-names></name>; <name><surname>Banda</surname><given-names>G.</given-names></name>; <name><surname>Lentini</surname><given-names>S. P.</given-names></name>; <name><surname>Das</surname><given-names>S.</given-names></name>; <name><surname>Xu</surname><given-names>Q.</given-names></name>; <name><surname>Keats</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>F.</given-names></name>; <name><surname>Wardwell</surname><given-names>S.</given-names></name>; <name><surname>Ning</surname><given-names>Y.</given-names></name>; <name><surname>Snodgrass</surname><given-names>J. T.</given-names></name>; <name><surname>Broudy</surname><given-names>M. I.</given-names></name>; <name><surname>Russian</surname><given-names>K.</given-names></name>; <name><surname>Zhou</surname><given-names>T.</given-names></name>; <name><surname>Commodore</surname><given-names>L.</given-names></name>; <name><surname>Narasimhan</surname><given-names>N. I.</given-names></name>; <name><surname>Mohemmad</surname><given-names>Q. K.</given-names></name>; <name><surname>Iuliucci</surname><given-names>J.</given-names></name>; <name><surname>Rivera</surname><given-names>V. M.</given-names></name>; <name><surname>Dalgarno</surname><given-names>D. C.</given-names></name>; <name><surname>Sawyer</surname><given-names>T. K.</given-names></name>; <name><surname>Clackson</surname><given-names>T.</given-names></name>; <name><surname>Shakespeare</surname><given-names>W. C.</given-names></name>
<article-title>Discovery
of 3-[2-(imidazo[1,2-b]pyridazin-3-Yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-Yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
(AP24534), a potent, orally active pan-inhibitor of breakpoint cluster
region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</article-title>. <source>J. Med. Chem.</source>
<year>2010</year>, <volume>53</volume> (<issue>12</issue>), <fpage>4701</fpage>&#x02013;<lpage>4719</lpage>. <pub-id pub-id-type="doi">10.1021/jm100395q</pub-id>.<pub-id pub-id-type="pmid">20513156</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Schoepfer</surname><given-names>J.</given-names></name>; <name><surname>Jahnke</surname><given-names>W.</given-names></name>; <name><surname>Berellini</surname><given-names>G.</given-names></name>; <name><surname>Buonamici</surname><given-names>S.</given-names></name>; <name><surname>Cotesta</surname><given-names>S.</given-names></name>; <name><surname>Cowan-Jacob</surname><given-names>S. W.</given-names></name>; <name><surname>Dodd</surname><given-names>S.</given-names></name>; <name><surname>Drueckes</surname><given-names>P.</given-names></name>; <name><surname>Fabbro</surname><given-names>D.</given-names></name>; <name><surname>Gabriel</surname><given-names>T.</given-names></name>; <name><surname>Groell</surname><given-names>J.-M.</given-names></name>; <name><surname>Grotzfeld</surname><given-names>R. M.</given-names></name>; <name><surname>Hassan</surname><given-names>A. Q.</given-names></name>; <name><surname>Henry</surname><given-names>C.</given-names></name>; <name><surname>Iyer</surname><given-names>V.</given-names></name>; <name><surname>Jones</surname><given-names>D.</given-names></name>; <name><surname>Lombardo</surname><given-names>F.</given-names></name>; <name><surname>Loo</surname><given-names>A.</given-names></name>; <name><surname>Manley</surname><given-names>P. W.</given-names></name>; <name><surname>Pell&#x000e9;</surname><given-names>X.</given-names></name>; <name><surname>Rummel</surname><given-names>G.</given-names></name>; <name><surname>Salem</surname><given-names>B.</given-names></name>; <name><surname>Warmuth</surname><given-names>M.</given-names></name>; <name><surname>Wylie</surname><given-names>A. A.</given-names></name>; <name><surname>Zoller</surname><given-names>T.</given-names></name>; <name><surname>Marzinzik</surname><given-names>A. L.</given-names></name>; <name><surname>Furet</surname><given-names>P.</given-names></name>
<article-title>Discovery of asciminib
(ABL001), an allosteric inhibitor of tyrosine kinase activity of BCR-ABL1</article-title>. <source>J. Med. Chem.</source>
<year>2018</year>, <volume>61</volume> (<issue>18</issue>), <fpage>8120</fpage>&#x02013;<lpage>8135</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01040</pub-id>.<pub-id pub-id-type="pmid">30137981</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Lamore</surname><given-names>S. D.</given-names></name>; <name><surname>Kohnken</surname><given-names>R. A.</given-names></name>; <name><surname>Peters</surname><given-names>M. F.</given-names></name>; <name><surname>Kolaja</surname><given-names>K. L.</given-names></name>
<article-title>Cardiovascular toxicity
induced by kinase inhibitors: Mechanisms and preclinical approaches</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2020</year>, <volume>33</volume> (<issue>1</issue>), <fpage>125</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.9b00387</pub-id>.<pub-id pub-id-type="pmid">31840498</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Doherty</surname><given-names>K. R.</given-names></name>; <name><surname>Wappel</surname><given-names>R. L.</given-names></name>; <name><surname>Talbert</surname><given-names>D. R.</given-names></name>; <name><surname>Trusk</surname><given-names>P. B.</given-names></name>; <name><surname>Moran</surname><given-names>D. M.</given-names></name>; <name><surname>Kramer</surname><given-names>J. W.</given-names></name>; <name><surname>Brown</surname><given-names>A. M.</given-names></name>; <name><surname>Shell</surname><given-names>S. A.</given-names></name>; <name><surname>Bacus</surname><given-names>S.</given-names></name>
<article-title>Multi-parameter
in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and
nilotinib in human cardiomyocytes</article-title>. <source>Toxicol.
Appli. Pharmacol.</source>
<year>2013</year>, <volume>272</volume> (<issue>1</issue>), <fpage>245</fpage>&#x02013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2013.04.027</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Hoy</surname><given-names>S. M.</given-names></name>
<article-title>Ponatinib:
A review of its use in adults with chronic myeloid leukaemia or Philadelphia
chromosome-positive acute lymphoblastic leukaemia</article-title>. <source>Drugs</source>
<year>2014</year>, <volume>74</volume> (<issue>7</issue>), <fpage>793</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-014-0216-6</pub-id>.<pub-id pub-id-type="pmid">24807266</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Rivera</surname><given-names>V. M.</given-names></name>; <name><surname>Pritchard</surname><given-names>J. R.</given-names></name>; <name><surname>Gonzalvez</surname><given-names>F.</given-names></name>; <name><surname>Baker</surname><given-names>T.</given-names></name>; <name><surname>Gozgit</surname><given-names>J. M.</given-names></name>; <name><surname>Hodgson</surname><given-names>G.</given-names></name>
<article-title>Comparative TKI profiling
analyses to explore potential
mechanisms of ponatinib-associated arterial thrombotic events</article-title>. <source>Blood</source>
<year>2014</year>, <volume>124</volume> (<issue>21</issue>), <fpage>1783</fpage><pub-id pub-id-type="doi">10.1182/blood.V124.21.1783.1783</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Latifi</surname><given-names>Y.</given-names></name>; <name><surname>Moccetti</surname><given-names>F.</given-names></name>; <name><surname>Wu</surname><given-names>M.</given-names></name>; <name><surname>Xie</surname><given-names>A.</given-names></name>; <name><surname>Packwood</surname><given-names>W.</given-names></name>; <name><surname>Qi</surname><given-names>Y.</given-names></name>; <name><surname>Ozawa</surname><given-names>K.</given-names></name>; <name><surname>Shentu</surname><given-names>W.</given-names></name>; <name><surname>Brown</surname><given-names>E.</given-names></name>; <name><surname>Shirai</surname><given-names>T.</given-names></name>; <name><surname>McCarty</surname><given-names>O. J.</given-names></name>; <name><surname>Ruggeri</surname><given-names>Z.</given-names></name>; <name><surname>Moslehi</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Druker</surname><given-names>B. J.</given-names></name>; <name><surname>L&#x000f3;pez</surname><given-names>J. A.</given-names></name>; <name><surname>Lindner</surname><given-names>J. R.</given-names></name>
<article-title>Thrombotic microangiopathy
as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine
kinase inhibitor ponatinib</article-title>. <source>Blood</source>
<year>2019</year>, <volume>133</volume> (<issue>14</issue>), <fpage>1597</fpage>&#x02013;<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2018-10-881557</pub-id>.<pub-id pub-id-type="pmid">30692122</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Hiwase</surname><given-names>D. K.</given-names></name>; <name><surname>Saunders</surname><given-names>V.</given-names></name>; <name><surname>Hewett</surname><given-names>D.</given-names></name>; <name><surname>Frede</surname><given-names>A.</given-names></name>; <name><surname>Zrim</surname><given-names>S.</given-names></name>; <name><surname>Dang</surname><given-names>P.</given-names></name>; <name><surname>Eadie</surname><given-names>L.</given-names></name>; <name><surname>Bik To</surname><given-names>L.</given-names></name>; <name><surname>Melo</surname><given-names>J.</given-names></name>; <name><surname>Kumar</surname><given-names>S.</given-names></name>; <name><surname>Hughes</surname><given-names>T. P.</given-names></name>; <name><surname>White</surname><given-names>D. L.</given-names></name>
<article-title>Dasatinib cellular
uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications</article-title>. <source>Clin. Cancer Res.</source>
<year>2008</year>, <volume>14</volume> (<issue>12</issue>), <fpage>3881</fpage>&#x02013;<lpage>3888</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5095</pub-id>.<pub-id pub-id-type="pmid">18559609</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Eadie</surname><given-names>L. N.</given-names></name>; <name><surname>Saunders</surname><given-names>V. A.</given-names></name>; <name><surname>Branford</surname><given-names>S.</given-names></name>; <name><surname>White</surname><given-names>D. L.</given-names></name>; <name><surname>Hughes</surname><given-names>T. P.</given-names></name>
<article-title>The new
allosteric inhibitor asciminib is susceptible to resistance mediated
by ABCB1 and ABCG2 overexpression <italic>in vitro</italic></article-title>. <source>Oncotarget</source>
<year>2018</year>, <volume>9</volume> (<issue>17</issue>), <fpage>13423</fpage>&#x02013;<lpage>13437</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.24393</pub-id>.<pub-id pub-id-type="pmid">29568367</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Redaelli</surname><given-names>S.</given-names></name>; <name><surname>Perini</surname><given-names>P.</given-names></name>; <name><surname>Ceccon</surname><given-names>M.</given-names></name>; <name><surname>Piazza</surname><given-names>R.</given-names></name>; <name><surname>Rigolio</surname><given-names>R.</given-names></name>; <name><surname>Mauri</surname><given-names>M.</given-names></name>; <name><surname>Boschelli</surname><given-names>F.</given-names></name>; <name><surname>Giannoudis</surname><given-names>A.</given-names></name>; <name><surname>Gambacorti-Passerini</surname><given-names>C.</given-names></name>
<article-title>In vitro and in vivo
identification of ABCB1 as an
efflux transporter of bosutinib</article-title>. <source>J. Hematol.
Oncol.</source>
<year>2015</year>, <volume>8</volume>, <fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s13045-015-0179-4</pub-id>.<pub-id pub-id-type="pmid">26149173</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Sun</surname><given-names>Y.-L.</given-names></name>; <name><surname>Patel</surname><given-names>A.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Chen</surname><given-names>Z.-S.</given-names></name>
<article-title>Role of ABC transporters
in cancer chemotherapy</article-title>. <source>Chin. J. Cancer.</source>
<year>2012</year>, <volume>31</volume> (<issue>2</issue>), <fpage>51</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.5732/cjc.011.10466</pub-id>.<pub-id pub-id-type="pmid">22257384</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Hill</surname><given-names>J.</given-names></name>; <name><surname>Hettikankanamalage</surname><given-names>A. A.</given-names></name>; <name><surname>Crich</surname><given-names>D.</given-names></name>
<article-title>Diversity-oriented
synthesis of <italic>N,N,O</italic>-trisubstituted hydroxylamines
from alcohols and amines by N-O bond formation</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2020</year>, <volume>142</volume> (<issue>35</issue>), <fpage>14820</fpage>&#x02013;<lpage>14825</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.0c05991</pub-id>.<pub-id pub-id-type="pmid">32803971</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Hill</surname><given-names>J.</given-names></name>; <name><surname>Beckler</surname><given-names>T. D.</given-names></name>; <name><surname>Crich</surname><given-names>D.</given-names></name>
<article-title>Recent advances
in the synthesis
of di- and trisubstituted hydroxylamines</article-title>. <source>Molecules</source>
<year>2023</year>, <volume>28</volume> (<issue>6</issue>), <fpage>2816</fpage><pub-id pub-id-type="doi">10.3390/molecules28062816</pub-id>.<pub-id pub-id-type="pmid">36985788</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Krasovskiy</surname><given-names>A.</given-names></name>; <name><surname>Knochel</surname><given-names>P.</given-names></name>
<article-title>A LiCl-mediated Br/Mg
exchange reaction for the preparation
of functionalized aryl- and heteroarylmagnesium compounds from organic
bromides</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2004</year>, <volume>43</volume> (<issue>25</issue>), <fpage>3333</fpage>&#x02013;<lpage>3336</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200454084</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Kyasa</surname><given-names>S.</given-names></name>; <name><surname>Meier</surname><given-names>R. N.</given-names></name>; <name><surname>Pardini</surname><given-names>R. A.</given-names></name>; <name><surname>Truttmann</surname><given-names>T. K.</given-names></name>; <name><surname>Kuwata</surname><given-names>K. T.</given-names></name>; <name><surname>Dussault</surname><given-names>P. H.</given-names></name>
<article-title>Synthesis of ethers via reaction
of carbanions and monoperoxyacetals</article-title>. <source>J. Org.
Chem.</source>
<year>2015</year>, <volume>80</volume> (<issue>24</issue>), <fpage>12100</fpage>&#x02013;<lpage>12114</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.5b02043</pub-id>.<pub-id pub-id-type="pmid">26560686</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Hoang</surname><given-names>K. M.</given-names></name>; <name><surname>Lees</surname><given-names>N. R.</given-names></name>; <name><surname>Herzon</surname><given-names>S. B.</given-names></name>
<article-title>Programmable synthesis of 2-deoxyglycosides</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2019</year>, <volume>141</volume> (<issue>20</issue>), <fpage>8098</fpage>&#x02013;<lpage>8103</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b03982</pub-id>.<pub-id pub-id-type="pmid">31059254</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Hoang</surname><given-names>K. M.</given-names></name>; <name><surname>Lees</surname><given-names>N. R.</given-names></name>; <name><surname>Herzon</surname><given-names>S. B.</given-names></name>
<article-title>General
method for the synthesis
of &#x003b1;- or &#x003b2;-deoxyaminoglycosides bearing basic nitrogen</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2021</year>, <volume>143</volume> (<issue>7</issue>), <fpage>2777</fpage>&#x02013;<lpage>2783</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.0c11262</pub-id>.<pub-id pub-id-type="pmid">33555855</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Nicolini</surname><given-names>F. E.</given-names></name>; <name><surname>Mauro</surname><given-names>M. J.</given-names></name>; <name><surname>Martinelli</surname><given-names>G.</given-names></name>; <name><surname>Kim</surname><given-names>D.-W.</given-names></name>; <name><surname>Soverini</surname><given-names>S.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>M. C.</given-names></name>; <name><surname>Hochhaus</surname><given-names>A.</given-names></name>; <name><surname>Cortes</surname><given-names>J.</given-names></name>; <name><surname>Chuah</surname><given-names>C.</given-names></name>; <name><surname>Dufva</surname><given-names>I. H.</given-names></name>; <name><surname>Apperley</surname><given-names>J. F.</given-names></name>; <name><surname>Yagasaki</surname><given-names>F.</given-names></name>; <name><surname>Pearson</surname><given-names>J. D.</given-names></name>; <name><surname>Peter</surname><given-names>S.</given-names></name>; <name><surname>Sanz Rodriguez</surname><given-names>C.</given-names></name>; <name><surname>Preudhomme</surname><given-names>C.</given-names></name>; <name><surname>Giles</surname><given-names>F.</given-names></name>; <name><surname>Goldman</surname><given-names>J. M.</given-names></name>; <name><surname>Zhou</surname><given-names>W.</given-names></name>
<article-title>Epidemiologic study
on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic
leukemia patients with BCR-ABL T315I mutation</article-title>. <source>Blood</source>
<year>2009</year>, <volume>114</volume> (<issue>26</issue>), <fpage>5271</fpage>&#x02013;<lpage>5278</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-04-219410</pub-id>.<pub-id pub-id-type="pmid">19843886</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Yazdanian</surname><given-names>M.</given-names></name>; <name><surname>Glynn</surname><given-names>S. L.</given-names></name>; <name><surname>Wright</surname><given-names>J. L.</given-names></name>; <name><surname>Hawi</surname><given-names>A.</given-names></name>
<article-title>Correlating
partitioning
and Caco-2 cell permeability of structurally diverse small molecular
weight compounds</article-title>. <source>Pharm. Res.</source>
<year>1998</year>, <volume>15</volume> (<issue>9</issue>), <fpage>1490</fpage>&#x02013;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1023/A:1011930411574</pub-id>.<pub-id pub-id-type="pmid">9755906</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Breeman</surname><given-names>R. B. V.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>
<article-title>Caco-2 cell permeability assays to measure drug absorption</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source>
<year>2005</year>, <volume>1</volume> (<issue>2</issue>), <fpage>175</fpage>&#x02013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.1.2.175</pub-id>.<pub-id pub-id-type="pmid">16922635</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Ames</surname><given-names>B. N.</given-names></name>; <name><surname>McCann</surname><given-names>J.</given-names></name>; <name><surname>Yamasaki</surname><given-names>E.</given-names></name>
<article-title>Methods for
detecting carcinogens
and mutagens with the Salmonella/mammalian-microsome mutagenicity
test</article-title>. <source>Mutat. Res.</source>
<year>1975</year>, <volume>31</volume> (<issue>6</issue>), <fpage>347</fpage>&#x02013;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1161(75)90046-1</pub-id>.<pub-id pub-id-type="pmid">768755</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Corvi</surname><given-names>R.</given-names></name>; <name><surname>Albertini</surname><given-names>S.</given-names></name>; <name><surname>Hartung</surname><given-names>T.</given-names></name>; <name><surname>Hoffmann</surname><given-names>S.</given-names></name>; <name><surname>Maurici</surname><given-names>D.</given-names></name>; <name><surname>Pfuhler</surname><given-names>S.</given-names></name>; <name><surname>Benthem</surname><given-names>J. V.</given-names></name>; <name><surname>Vanparys</surname><given-names>P.</given-names></name>
<article-title>ECVAM Retrospective
validation of <italic>in vitro</italic> micronucleus test (MNT)</article-title>. <source>Mutagenesis</source>
<year>2008</year>, <volume>23</volume> (<issue>4</issue>), <fpage>271</fpage>&#x02013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1093/mutage/gen010</pub-id>.<pub-id pub-id-type="pmid">18326866</pub-id>
</mixed-citation></ref><ref id="ref51"><note id="cit51"><p>The 50 mg/kg po and 5 mg/kg iv
dosing was selected for single-dose PK studies in mice to achieve
comparable exposures relative to bosutinib. According to page 40 of
the &#x0201c;Pharmacology Review(s)&#x0201d; report of the new drug
application (NDA) for bosutinib [application no. 203341; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341_bosulif_toc.cfm">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341_bosulif_toc.cfm</uri> (accessed 2023&#x02013;02&#x02013;13)], bosutinib achieved a <italic>C</italic><sub>max</sub> = 1509 nM and AUC<sub>inf</sub> = 11&#x0202f;677
h&#x000b7;nM at 50 mg/kg po and 5 mg/kg iv dosing in nude mice.</p></note></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name>
<article-title>Designing
around structural alerts in drug discovery</article-title>. <source>J. Med. Chem.</source>
<year>2020</year>, <volume>63</volume> (<issue>12</issue>), <fpage>6276</fpage>&#x02013;<lpage>6302</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00917</pub-id>.<pub-id pub-id-type="pmid">31497963</pub-id>
</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Griffen</surname><given-names>E.</given-names></name>; <name><surname>Leach</surname><given-names>A. G.</given-names></name>; <name><surname>Robb</surname><given-names>G. R.</given-names></name>; <name><surname>Warner</surname><given-names>D. J.</given-names></name>
<article-title>Matched molecular
pairs as a medicinal chemistry tool</article-title>. <source>J. Med.
Chem.</source>
<year>2011</year>, <volume>54</volume> (<issue>22</issue>), <fpage>7739</fpage>&#x02013;<lpage>7750</lpage>. <pub-id pub-id-type="doi">10.1021/jm200452d</pub-id>.<pub-id pub-id-type="pmid">21936582</pub-id>
</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Morgenthaler</surname><given-names>M.</given-names></name>; <name><surname>Schweizer</surname><given-names>E.</given-names></name>; <name><surname>Hoffmann-R&#x000f6;der</surname><given-names>A.</given-names></name>; <name><surname>Benini</surname><given-names>F.</given-names></name>; <name><surname>Martin</surname><given-names>R. E.</given-names></name>; <name><surname>Jaeschke</surname><given-names>G.</given-names></name>; <name><surname>Wagner</surname><given-names>B.</given-names></name>; <name><surname>Fischer</surname><given-names>H.</given-names></name>; <name><surname>Bendels</surname><given-names>S.</given-names></name>; <name><surname>Zimmerli</surname><given-names>D.</given-names></name>; <name><surname>Schneider</surname><given-names>J.</given-names></name>; <name><surname>Diederich</surname><given-names>F.</given-names></name>; <name><surname>Kansy</surname><given-names>M.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>K.</given-names></name>
<article-title>Predicting
and tuning physicochemical properties in lead optimization: Amine
basicities</article-title>. <source>ChemMedChem.</source>
<year>2007</year>, <volume>2</volume> (<issue>8</issue>), <fpage>1100</fpage>&#x02013;<lpage>1115</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200700059</pub-id>.<pub-id pub-id-type="pmid">17530727</pub-id>
</mixed-citation></ref></ref-list></back></article>
